QIAGEN Sample & Assay Technologies From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Sample & Assay Technologies Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics, applied testing markets and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations for certain events including funding, budgets, and others), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with or furnished to the U.S. Securities and Exchange Commission (SEC). -8- Sample & Assay Technologies Our Future Sample & Assay Technologies will have a major impact on ■ Life Sciences research ■ Pharmaceutical drug development ■ Applied Markets ■ In-Vitro Diagnostics Our role and goals are well defined We have a great starting position Great opportunities -9- Sample & Assay Technologies 1 QIAGEN’s Leadership Formula 1. 2. Focus Bundle strengths Lead in terms of resources Leverage focus Lead ■ 3. Constant race Take Leadership Global Act local, leverage global resources Global matrix - 10 - Sample & Assay Technologies QIAGEN – Full Circle – One Core Focus Academic Research Molecular Diagnostics Sample Technologies Pharma/Clinical Assay Technologies Applied Markets From Invention to Application to Patients Sample & Assay Technologies Play Central Role - 11 - Sample & Assay Technologies 2 QIAGEN – Full Circle – One Core Focus Academic Research Molecular Diagnostics Sample Technologies Assay Technologies Pharma/Clinical Applied Markets - 12 - Sample & Assay Technologies QIAGEN – Full Circle – One Core Focus Academic Research Molecular Diagnostics Sample Technologies Pharma/Clinical Assay Technologies Applied Markets - 13 - Sample & Assay Technologies 3 QIAGEN – Full Circle – One Core Focus Academic Research Molecular Diagnostics Sample Technologies Assay Technologies Pharma/Clinical Applied Markets - 14 - Sample & Assay Technologies From Invention to Application to Patients Sample & Assay Technologies Play Central Role Academic Research Molecular Diagnostics Sample Technologies Pharma/Clinical Assay Technologies Applied Markets - 15 - Sample & Assay Technologies 4 QIAGEN – Full Circle – One Core Focus Our current capabilities provide the basis for ■ Molecular diagnostics: leadership ■ Pharma: hotwiring clinical development and MDx ■ Applied Markets: dissemination of molecular biology ■ Academia: a close relationship with innovation ….and all without loss of focus as the core capabilities stay the same. - 16 - Sample & Assay Technologies Leadership in All Market Segments in our Core Academia Market leader Applied Testing Market leader SAMPLE Technologies - 17 - Pharma Market leader Molecular Diagnostics Market leader ASSAY Technologies Sample & Assay Technologies 5 Leading Position – Broad Footprint OEM >20 relationships Sample Technologies Transplantation • Leading SSP Franchise • New: sequence-based ~$400 Million HPV Franchise Real-time PCR assays • 120 assays RUO • 40 with regulatory approval - 18 - Sample & Assay Technologies Market Leadership in MDx Molecular Diagnostic Landscape (1) Leading Market Positions Sales in US$ millions Largest infectious disease assay portfolio 450 400 ~ 400 Largest R&D budget in molecular technologies 350 Largest sales & marketing force 330 Extensive IP and technology portfolio 300 No. 2 in PCR technology in MDx 250 200 200 150 No. 1 in HPV testing 130 No. 1 in automated sample processing 120 No. 1 in manual sample preparation 100 60 40 50 No. 1 in PCR/SSP HLA testing (#3 overall) av e W Th ird ep he id C Ba ye r Ab bo tt ob e x D M en pr G IA G Q R oc he EN 0 (1) Excluding Viral Load and Blood banking business - 19 - Sample & Assay Technologies 6 QIAGEN With Record Sales and Double Digit Growth 1.000 900 850 800 750 700 650 600 CAGR = 20%+ 550 500 450 400 350 300 250 200 2003 2004 2005 2006 2007E(1) (1) Analyst estimates - 20 - Sample & Assay Technologies QIAGEN With Record Sales and Double Digit Growth 1.000 900 2008 850 $875-905 800 750 700 650 600 CAGR = 20%+ 550 500 450 400 350 300 250 200 2003 2004 2005 2006 2007 2008E(1) (1) Refer to Company‘s guidance - 21 - Sample & Assay Technologies 7 QIAGEN’s Revenue Distribution Consumable growth increased By Product Groups ■ Increasing trend ■ Innovation-driven Consumables Sample technologies Assay technologies Instrumentation ■ Very strong performance ■ Great pipeline 90% ■ QIAcube ■ BR 8000 Universal and MDx 10% Instruments Selling Solutions - 22 - Sample & Assay Technologies QIAGEN’s Revenue Distribution By Geographic Regions Globalization continues ■ 2007: Turkey, Spain, Brazil, Luxemburg, Hong Kong ■ 2008: incl. Eastern Europe and Latin America Asia RoW 3% of sales Global rollout of Women‘s Health portfolio gives mass ■ Has huge opportunity to go global 9% 13% 46% 36% Europe ■ Big jump in US share in 2007 due to WH addition 39% 52% North America Go Global – Act Local - 23 - Sample & Assay Technologies 8 QIAGEN’s Revenue Distribution Life Sciences ■ Major innovation initiatives ■ Significant focus ■ More resources than ever By Customer Groups Molecular Diagnostics Applied Testing 11% 8% 27% 48% 27% 24% Applied Testing ■ cador assay portfolio ■ Forensic packages Pharma ■ Successes – a lot of opportunities Molecular Diagnostics ■ Critical mass - leading position ■ Significant room to grow 17% Pharmaceutical Industry Research Tailored Sales and Marketing Channels - 24 - Sample & Assay Technologies New Records in Innovation Products < 1 years old # of launched products Revenue share Revenues 72 ~4 % > $15 MM Products < 3 years old # of launched products Revenue share(1) Revenues 170 ~17 % > $75 MM Exceeded Innovation Targets …. Again (1) Pre-merger QIAGEN for E&I, Jp, NA - 25 - Sample & Assay Technologies 9 New Records in Innovation - 26 - Sample & Assay Technologies QIAsymphony (SP Module) 2008 - 27 - Sample & Assay Technologies 10 QIAsymphony More than 400 man years 3 QIAGEN development sites Supported by 12 external development partners The first module in a revolutionary series - 28 - Sample & Assay Technologies - 29 - Sample & Assay Technologies QIAxcel 11 EZ1 Advanced - 30 - Sample & Assay Technologies 1 Billion Samples Extracted with QIAGEN Sample Technologies 1 Billion Sample Technology Products Sold - 31 - Sample & Assay Technologies 12 ~15 Million Diagnostic Tests Sold in 2007 ~15 MM Diagnostic Assays Sold in 2007 - 32 - Sample & Assay Technologies Mergers and Acquisitions (I) - 33 - Sample & Assay Technologies 13 Landmark Merger and Acquisitions (II) - 34 - Sample & Assay Technologies Integration well on Track Resources FTE 50 40 30 Phase 4 Plan 20 HR, Budget 08, Going Direct Implement new business processes 10 Transfer of projects to line Apr PrePlaning May Jun Jul PreClosing Announcement Aug Sep Oct Nov PostClosing Dec Jan Feb Mar Apr New Budget 2008 and Going direct DAY 1 - 35 - Jun Line functions take over all responsibilities Implementation Closing May TODAY Certain integration projects continue Sample & Assay Technologies 14 Meeting Integration Milestones Project Up-date > 80 integration projects ongoing ~ 525 high level project milestones identified > 50% of milestones achieved Synergy targets Revenues: synergies accelerate 2009 Costs: ~ $35-45 million in 2008 Thereof - 36 - COS 10% - 15% R&D 20% - 25% S&M 20% - 25% G&A 45% - 50% Sample & Assay Technologies Our Goals 2008 Goals Classes for 2008 Financial Exceed/meet financial targets Strategic Increase strategic value: “Standardization-Dissemination-Systems Biology” Operational Operational Excellence - Processes - Organization Communication Increase clarity and awareness of our mission and value propositions HR Create employee base which excels in terms of talent and engagement Make QIAGEN an even better place to work Integration Together we are stronger: Fast integration, fast results for our customers and patients - 37 - Sample & Assay Technologies 15 Key: Synchronized Translation of Goals General Goals General Corporate 6 Major Goals ~ 200 Sub-goals EC - Functional Measurable Actionable On Intranet Measure progress Global Organization - 38 - Delegate Manage Monitor Sample & Assay Technologies Outlook 2008 Execution on strategy Standardization – Dissemination – Convergence Four customer segments for same core Innovation focus continues 2008 launches extremely important Launches delivering results Assay expansion, platform advancements Content expansion Integrations Globalization - 39 - Sample & Assay Technologies 16 Questions & Answers - 40 - Sample & Assay Technologies 17